Chester County News and Community Website
Galera Therapeutics, Inc. (Nasdaq: GRTX), headquartered in Malvern, PA, is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, …
Galera to Present at Piper Sandler Annual Healthcare Conference Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) recently reported financial results for the third quarter that ended September 30, 2022 and provided recent corporate updates.
Galera Reports Third Quarter 2022 Financial Results Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that tumor outcomes data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis (SOM) and final data from …
Galera to Present at 2022 American Society for Radiation Oncology Annual Meeting Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual …
Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced the recent appointment of Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer (CMO).
Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced financial results for the second quarter ended June 30, 2022 and provided recent corporate updates.
Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced results from the open-label Phase 1 stage of the GRECO-1 trial of rucosopasem in combination with stereotactic body radiation therapy (SBRT) …
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) states that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, …
Galera to Present at Jefferies Healthcare Conference Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) recently announced data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis will be highlighted in an oral presentation …
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) this week announced its intent to file a New Drug Application (NDA) for avasopasem manganese (avasopasem) for the treatment of radiotherapy-induced severe …
Galera Announces Plan to Submit Avasopasem NDA by Year End Read More